GlassScriptPhysician profile
Rosemary E Kelley
NPI 1467593830
$390.72
in general payments reported to CMS, 2019-2025
11 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $144.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.56 | 2021 | |
| Valinor Pharma, LLC | $24.29 | 2025 | Movantik |
| Virtus Pharmaceuticals LLC | $20.89 | 2025 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.24 | 2025 | Relistor |
| Globus Medical, INC. | $18.71 | 2025 | Senza |
| Vertex Pharmaceuticals Incorporated | $17.70 | 2025 | |
| Esperion Therapeutics, INC. | $17.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.93 | 2021 | |
| Currax Pharmaceuticals LLC | $13.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.